John Kim
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 15 | 2025 | 654 | 3.860 |
Why?
| | Idiopathic Pulmonary Fibrosis | 20 | 2025 | 658 | 3.430 |
Why?
| | Cardiac Surgical Procedures | 4 | 2022 | 589 | 1.420 |
Why?
| | Cardiopulmonary Bypass | 2 | 2022 | 220 | 1.200 |
Why?
| | Heart Defects, Congenital | 4 | 2021 | 884 | 1.160 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2023 | 317 | 1.100 |
Why?
| | Thrombosis | 2 | 2021 | 399 | 0.950 |
Why?
| | Hemodynamics | 2 | 2021 | 1100 | 0.930 |
Why?
| | HLA-DRB1 Chains | 1 | 2025 | 112 | 0.850 |
Why?
| | Poisoning | 1 | 2025 | 120 | 0.830 |
Why?
| | Lung | 12 | 2025 | 4137 | 0.820 |
Why?
| | Shock | 1 | 2025 | 103 | 0.820 |
Why?
| | Rheumatic Diseases | 4 | 2024 | 92 | 0.800 |
Why?
| | Mucin-5B | 2 | 2025 | 222 | 0.800 |
Why?
| | Pulmonary Fibrosis | 2 | 2024 | 399 | 0.790 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2025 | 345 | 0.790 |
Why?
| | Pyridones | 2 | 2023 | 188 | 0.780 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 40 | 0.770 |
Why?
| | Tomography, X-Ray Computed | 14 | 2025 | 2765 | 0.760 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2023 | 142 | 0.740 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 230 | 0.710 |
Why?
| | Biomarkers | 9 | 2025 | 4190 | 0.700 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 93 | 0.690 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2021 | 56 | 0.660 |
Why?
| | Indoles | 2 | 2023 | 478 | 0.650 |
Why?
| | Autoimmune Diseases | 4 | 2024 | 465 | 0.640 |
Why?
| | Rheumatology | 4 | 2024 | 115 | 0.640 |
Why?
| | Resistin | 1 | 2019 | 11 | 0.630 |
Why?
| | Arthritis, Rheumatoid | 3 | 2025 | 1178 | 0.620 |
Why?
| | Proteomics | 6 | 2025 | 1138 | 0.610 |
Why?
| | Asymptomatic Diseases | 1 | 2019 | 92 | 0.600 |
Why?
| | Sleep Deprivation | 1 | 2021 | 206 | 0.600 |
Why?
| | Ketorolac | 1 | 2018 | 25 | 0.580 |
Why?
| | Lung Injury | 1 | 2021 | 227 | 0.580 |
Why?
| | Humans | 63 | 2025 | 141754 | 0.560 |
Why?
| | Platelet Aggregation | 1 | 2018 | 112 | 0.560 |
Why?
| | Leptin | 1 | 2019 | 242 | 0.550 |
Why?
| | Electrocardiography | 1 | 2021 | 618 | 0.550 |
Why?
| | Vital Capacity | 4 | 2023 | 306 | 0.550 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 185 | 0.550 |
Why?
| | Adiponectin | 1 | 2019 | 244 | 0.540 |
Why?
| | Aged | 24 | 2025 | 24746 | 0.540 |
Why?
| | Male | 35 | 2025 | 70179 | 0.480 |
Why?
| | Prospective Studies | 14 | 2025 | 7777 | 0.470 |
Why?
| | Psychotherapy, Brief | 1 | 2015 | 39 | 0.450 |
Why?
| | Female | 36 | 2025 | 75943 | 0.450 |
Why?
| | Cardiovascular Agents | 1 | 2016 | 156 | 0.430 |
Why?
| | Sleep | 1 | 2021 | 885 | 0.430 |
Why?
| | Social Work | 1 | 2015 | 85 | 0.430 |
Why?
| | Tissue Expansion Devices | 1 | 2013 | 5 | 0.410 |
Why?
| | Middle Aged | 23 | 2025 | 34647 | 0.400 |
Why?
| | Breast Implants | 1 | 2013 | 20 | 0.390 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2011 | 281 | 0.380 |
Why?
| | Free Tissue Flaps | 1 | 2013 | 47 | 0.380 |
Why?
| | Mammaplasty | 1 | 2013 | 119 | 0.340 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.330 |
Why?
| | Critical Care | 1 | 2016 | 650 | 0.320 |
Why?
| | Genome-Wide Association Study | 4 | 2025 | 1406 | 0.320 |
Why?
| | Thrombelastography | 3 | 2020 | 175 | 0.320 |
Why?
| | Child | 14 | 2025 | 22414 | 0.320 |
Why?
| | Disease Progression | 5 | 2025 | 2800 | 0.320 |
Why?
| | Independent Living | 2 | 2021 | 112 | 0.300 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 337 | 0.290 |
Why?
| | Postoperative Period | 2 | 2021 | 361 | 0.290 |
Why?
| | Muscle, Skeletal | 6 | 2011 | 1757 | 0.290 |
Why?
| | Atherosclerosis | 2 | 2025 | 404 | 0.290 |
Why?
| | Blood Coagulation Disorders | 2 | 2020 | 189 | 0.280 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1942 | 0.270 |
Why?
| | Adolescent | 6 | 2025 | 22130 | 0.250 |
Why?
| | Obesity | 1 | 2019 | 3008 | 0.240 |
Why?
| | Oxidants | 1 | 2006 | 112 | 0.240 |
Why?
| | Child, Preschool | 5 | 2025 | 11512 | 0.230 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 562 | 0.230 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 66 | 0.220 |
Why?
| | Smoking | 2 | 2025 | 1603 | 0.220 |
Why?
| | Cohort Studies | 7 | 2025 | 5815 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 4 | 2025 | 2375 | 0.210 |
Why?
| | Adult | 6 | 2024 | 39391 | 0.210 |
Why?
| | Rheumatoid Factor | 1 | 2025 | 177 | 0.210 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2025 | 118 | 0.200 |
Why?
| | Eicosapentaenoic Acid | 1 | 2023 | 38 | 0.200 |
Why?
| | Smokers | 2 | 2025 | 144 | 0.200 |
Why?
| | Carbon Monoxide | 1 | 2023 | 83 | 0.200 |
Why?
| | Glucocorticoids | 2 | 2024 | 534 | 0.200 |
Why?
| | Peptides, Cyclic | 1 | 2025 | 266 | 0.200 |
Why?
| | Demography | 1 | 2024 | 296 | 0.200 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2903 | 0.200 |
Why?
| | Antibody Formation | 1 | 2024 | 298 | 0.190 |
Why?
| | Methylprednisolone | 1 | 2022 | 64 | 0.190 |
Why?
| | Angiopoietin-2 | 1 | 2022 | 15 | 0.190 |
Why?
| | Heart Failure | 2 | 2021 | 2093 | 0.190 |
Why?
| | Acetylcysteine | 1 | 2022 | 144 | 0.180 |
Why?
| | Infant | 5 | 2025 | 9843 | 0.180 |
Why?
| | Insulin | 5 | 2022 | 2491 | 0.180 |
Why?
| | Alleles | 1 | 2025 | 891 | 0.180 |
Why?
| | Myofibroblasts | 1 | 2023 | 128 | 0.180 |
Why?
| | Vasodilation | 1 | 2025 | 516 | 0.170 |
Why?
| | Tomography | 1 | 2021 | 45 | 0.170 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2022 | 93 | 0.170 |
Why?
| | Respiratory System Abnormalities | 1 | 2021 | 18 | 0.170 |
Why?
| | Blood Loss, Surgical | 1 | 2022 | 112 | 0.170 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 284 | 0.170 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5697 | 0.170 |
Why?
| | Proportional Hazards Models | 4 | 2025 | 1268 | 0.170 |
Why?
| | Actigraphy | 1 | 2021 | 126 | 0.170 |
Why?
| | Femoral Vein | 1 | 2020 | 35 | 0.170 |
Why?
| | Lung Transplantation | 1 | 2024 | 322 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2024 | 11181 | 0.170 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2257 | 0.170 |
Why?
| | Photoplethysmography | 1 | 2020 | 18 | 0.160 |
Why?
| | Heart Diseases | 1 | 2023 | 335 | 0.160 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 91 | 0.160 |
Why?
| | Arterial Switch Operation | 1 | 2020 | 15 | 0.160 |
Why?
| | Risk Factors | 5 | 2025 | 10482 | 0.160 |
Why?
| | Proof of Concept Study | 1 | 2020 | 85 | 0.160 |
Why?
| | Vital Signs | 1 | 2020 | 47 | 0.160 |
Why?
| | Promoter Regions, Genetic | 1 | 2025 | 1243 | 0.160 |
Why?
| | Body Mass Index | 2 | 2019 | 2385 | 0.160 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 238 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 62 | 0.160 |
Why?
| | Thorax | 1 | 2020 | 50 | 0.160 |
Why?
| | Herniorrhaphy | 1 | 2020 | 76 | 0.160 |
Why?
| | Antibodies, Viral | 1 | 2024 | 656 | 0.160 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.160 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 87 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 52 | 0.150 |
Why?
| | Logistic Models | 1 | 2025 | 2092 | 0.150 |
Why?
| | Coronary Angiography | 1 | 2021 | 316 | 0.150 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 116 | 0.150 |
Why?
| | Peritoneal Dialysis | 1 | 2020 | 97 | 0.150 |
Why?
| | Transcriptome | 2 | 2024 | 1014 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 556 | 0.140 |
Why?
| | Pulmonary Valve | 1 | 2020 | 96 | 0.140 |
Why?
| | Oxidative Stress | 3 | 2011 | 1334 | 0.140 |
Why?
| | Education, Nursing, Continuing | 1 | 2018 | 50 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2024 | 799 | 0.140 |
Why?
| | Acute Disease | 1 | 2021 | 1010 | 0.140 |
Why?
| | Length of Stay | 2 | 2021 | 1263 | 0.140 |
Why?
| | Learning Curve | 1 | 2018 | 70 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 471 | 0.140 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2017 | 33 | 0.140 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2020 | 270 | 0.140 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2020 | 208 | 0.130 |
Why?
| | Catheterization, Peripheral | 1 | 2018 | 108 | 0.130 |
Why?
| | Glucose | 6 | 2011 | 1041 | 0.130 |
Why?
| | Hand | 1 | 2018 | 163 | 0.130 |
Why?
| | Stroke Volume | 1 | 2020 | 590 | 0.130 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 155 | 0.130 |
Why?
| | Autoantibodies | 1 | 2025 | 1475 | 0.130 |
Why?
| | Young Adult | 3 | 2021 | 13749 | 0.130 |
Why?
| | Insulin Receptor Substrate Proteins | 4 | 2011 | 60 | 0.130 |
Why?
| | Circadian Rhythm | 1 | 2021 | 515 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2135 | 0.130 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 540 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1866 | 0.120 |
Why?
| | Polysomnography | 1 | 2017 | 241 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 127 | 0.120 |
Why?
| | Scimitar Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
| | Adiposity | 1 | 2021 | 521 | 0.120 |
Why?
| | Infant, Newborn | 4 | 2023 | 6289 | 0.120 |
Why?
| | Rats, Zucker | 4 | 2011 | 33 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 768 | 0.120 |
Why?
| | Algorithms | 2 | 2022 | 1768 | 0.120 |
Why?
| | Coronary Care Units | 1 | 2016 | 23 | 0.120 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2016 | 62 | 0.120 |
Why?
| | Nitrous Oxide | 1 | 2016 | 34 | 0.120 |
Why?
| | Hemoptysis | 1 | 2016 | 37 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2075 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 348 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2011 | 1225 | 0.120 |
Why?
| | Linear Models | 1 | 2017 | 858 | 0.110 |
Why?
| | Pilot Projects | 1 | 2021 | 1826 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.110 |
Why?
| | Calcium Channel Blockers | 1 | 2016 | 172 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 820 | 0.110 |
Why?
| | Vaccination | 1 | 2024 | 1472 | 0.110 |
Why?
| | Glycogen Synthase | 4 | 2007 | 6 | 0.110 |
Why?
| | China | 1 | 2015 | 220 | 0.110 |
Why?
| | Health Status | 1 | 2020 | 824 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2020 | 747 | 0.110 |
Why?
| | Femoral Neoplasms | 1 | 2014 | 9 | 0.110 |
Why?
| | Muscle Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
| | Hydrogen Peroxide | 4 | 2011 | 339 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2016 | 330 | 0.100 |
Why?
| | Fever of Unknown Origin | 1 | 2014 | 13 | 0.100 |
Why?
| | Motor Activity | 1 | 2018 | 720 | 0.100 |
Why?
| | Hemangioma | 1 | 2014 | 45 | 0.100 |
Why?
| | Aging | 1 | 2024 | 1924 | 0.100 |
Why?
| | Scleroderma, Systemic | 2 | 2024 | 122 | 0.100 |
Why?
| | Arthralgia | 1 | 2014 | 57 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2020 | 897 | 0.090 |
Why?
| | United States | 4 | 2025 | 15310 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1656 | 0.090 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 95 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 1205 | 0.080 |
Why?
| | Rats | 6 | 2011 | 5637 | 0.080 |
Why?
| | Knee Joint | 1 | 2014 | 411 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 859 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2020 | 2821 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2007 | 82 | 0.070 |
Why?
| | Anticoagulants | 2 | 2023 | 675 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7923 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2023 | 16374 | 0.060 |
Why?
| | Hypertension | 2 | 2005 | 1254 | 0.060 |
Why?
| | Critical Illness | 2 | 2023 | 837 | 0.060 |
Why?
| | Free Radicals | 1 | 2006 | 114 | 0.060 |
Why?
| | Renin | 1 | 2005 | 34 | 0.060 |
Why?
| | Tetrazoles | 1 | 2005 | 45 | 0.060 |
Why?
| | Mass Screening | 2 | 2024 | 1313 | 0.060 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 38 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2938 | 0.060 |
Why?
| | Biphenyl Compounds | 1 | 2005 | 71 | 0.060 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2024 | 9 | 0.050 |
Why?
| | Spirometry | 1 | 2025 | 260 | 0.050 |
Why?
| | Sjogren's Syndrome | 1 | 2024 | 53 | 0.050 |
Why?
| | Walk Test | 1 | 2024 | 80 | 0.050 |
Why?
| | Myositis | 1 | 2024 | 52 | 0.050 |
Why?
| | Forced Expiratory Volume | 1 | 2025 | 484 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2023 | 37 | 0.050 |
Why?
| | Mouth | 1 | 2024 | 88 | 0.050 |
Why?
| | Vitamin K | 1 | 2023 | 42 | 0.050 |
Why?
| | California | 1 | 2025 | 466 | 0.050 |
Why?
| | Connective Tissue Diseases | 1 | 2024 | 85 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2025 | 180 | 0.050 |
Why?
| | Proprotein Convertases | 1 | 2023 | 16 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 111 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 2023 | 127 | 0.050 |
Why?
| | Blood Proteins | 1 | 2024 | 250 | 0.050 |
Why?
| | Osteopontin | 1 | 2022 | 31 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2022 | 34 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2024 | 560 | 0.050 |
Why?
| | Quality Improvement | 1 | 2021 | 1254 | 0.050 |
Why?
| | Europe | 1 | 2023 | 411 | 0.050 |
Why?
| | Pulmonary Emphysema | 1 | 2025 | 312 | 0.050 |
Why?
| | Metalloproteases | 1 | 2022 | 43 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 169 | 0.050 |
Why?
| | Exome | 1 | 2023 | 238 | 0.050 |
Why?
| | Child, Hospitalized | 1 | 2022 | 53 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2024 | 239 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 558 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 467 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 363 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1320 | 0.040 |
Why?
| | Biological Transport | 3 | 2007 | 410 | 0.040 |
Why?
| | Water-Electrolyte Balance | 1 | 2020 | 32 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2024 | 1502 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 750 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 482 | 0.040 |
Why?
| | Genetic Variation | 1 | 2025 | 1000 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 760 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 807 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 490 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2022 | 924 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2022 | 1989 | 0.030 |
Why?
| | Trauma Centers | 1 | 2020 | 450 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1492 | 0.030 |
Why?
| | Genotype | 1 | 2022 | 1866 | 0.030 |
Why?
| | Fibroblasts | 1 | 2023 | 1021 | 0.030 |
Why?
| | Lung Diseases | 1 | 2024 | 793 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 276 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2018 | 197 | 0.030 |
Why?
| | Nurse's Role | 1 | 2018 | 167 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 761 | 0.030 |
Why?
| | Animals | 6 | 2011 | 37749 | 0.030 |
Why?
| | Receptor, Insulin | 2 | 2007 | 100 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1634 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2806 | 0.030 |
Why?
| | Signal Transduction | 2 | 2006 | 5169 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4080 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 1027 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 871 | 0.030 |
Why?
| | Registries | 1 | 2022 | 2144 | 0.030 |
Why?
| | Phosphoproteins | 2 | 2005 | 338 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3177 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3014 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 811 | 0.020 |
Why?
| | Glycogen | 1 | 2007 | 54 | 0.020 |
Why?
| | Pyridines | 1 | 2011 | 557 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 2014 | 857 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2005 | 39 | 0.010 |
Why?
| | Angiotensin II | 1 | 2005 | 99 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 919 | 0.010 |
Why?
| | Oncogene Proteins | 1 | 2005 | 63 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 324 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 242 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1774 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1094 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2005 | 368 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2005 | 444 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2525 | 0.010 |
Why?
| | Mice | 1 | 2005 | 18109 | 0.000 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|